Pan-HDAC inhibitors, such as TSA, SAHA, valproate, and sodium butyrate, reduced neuroinflammatory responses and exhibited neuroprotective effects in rodent models of stroke, neurodegenerative disease, or acute brain injury [16,44]. This evidence concerns the gene HDAC9 and stroke disorder.